Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning, happy Tuesday. I was

ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a label update for its ADHD treatment,

A large study of 30,000 adults diagnosed with ADHD in the U.K. found women with ADHD died roughly nine years younger than women without a diagnosis. Men had about a seven-year shorter lifespan.

The Food and Drug Administration announced last week that it will revoke authorization for FD&C Red No. 3 in food and ingested drugs under the Delaney Clause of the Federal Food, Drug, and Cosmetic Act. Red No. 3, a synthetic food dye, gives products like candies, frosting and frozen desserts their bright, cherry-red color.

Akili’s new era as a subsidiary of Virtual Therapeutics will start with FDA approval of its digital therapeutic for attention-deficit hyperactivity disorder (ADHD) in adults, a key part of its ...

A national shortage in a common treatment for attention-deficit hyperactivity disorder was associated with changes in stimulant prescriptions filled for children over recent years, a new study suggests.

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to

has announced the FDA approval of a label update for its ADHD treatment, Qelbree. The company, currently valued at $2.1 billion and trading near its 52-week high, has received FDA approval for ...